| Code | CSB-RA013481MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Bepranemab, targeting microtubule-associated protein tau (MAPT). MAPT plays a crucial role in stabilizing microtubules in neuronal cells and maintaining axonal transport. Under pathological conditions, MAPT undergoes hyperphosphorylation and forms abnormal aggregates, leading to neurofibrillary tangles that are hallmark features of Alzheimer's disease and other tauopathies. These tau pathologies correlate strongly with cognitive decline and neurodegeneration, making MAPT a critical therapeutic target in neurodegenerative disease research.
Bepranemab is a humanized IgG4 monoclonal antibody designed to target specific tau epitopes associated with pathological aggregation. This biosimilar antibody provides researchers with a valuable tool for investigating tau biology, studying mechanisms of tau-mediated neurodegeneration, and exploring potential therapeutic interventions in tauopathies. It enables examination of tau protein dynamics, aggregate formation, and clearance pathways in various experimental models of neurodegenerative disorders.
There are currently no reviews for this product.